- Relief Therapeutics (OTCQB:RLFTY) has granted an exclusive license to Eton Pharmaceuticals (NASDAQ:ETON) for the commercialization of GOLIKE family of products in the United States, it said Friday.
- PKU GOLIKE is a commercial ultra-rare disease medical formula complementary to Eton’s existing metabolic franchise and specialty call point.
- “This transition is fully aligned with Relief’s strategy of moving the GOLIKE products into partnership models in the U.S. and Europe,” Michelle Lock, interim CEO of Relief said.
- Relief will receive an upfront payment of $2.2 million and is eligible to receive an additional $2 million in sales milestones payments as well as mid-teens royalties on net sales, the company said in a statement.
- PKU GOLIKE’s annualized net sales exceeded $1 million in the U.S. in Q4.
- Additionally, Eton also received U.S. rights to Relief’s GOLIKE Medical Food line extensions under development for the management of other inherited rare metabolic diseases such as tyrosinemia and homocystinuria, which are both expected to launch in 2025 and 2026 under the same trademark.
- Source: Press Release
More on Eton Pharmaceuticals, Relief Therapeutics Holding SA, etc.
By Press Room
